JavaScript is disabled. Please enable to continue!
Media Centre >> Press Releases >> 2019-04-15

Eurofins announces a buy-back of a minority stake owned by biologists in Eurofins Laboratoire des Pyramides (France)

Sidebar Image

Monday, April 15, 2019

Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing, announces a buy-back of a minority stake owned by two biologists in Eurofins Laboratoire des Pyramides (“Eurofins LDP”). The biologists have decided to indirectly reinvest part of their proceeds from the buy-back of their shares in Eurofins LDP by subscribing, pursuant to the terms of article 8bis of Eurofins’ articles of association (capital autorisé) to a reserved capital increase through a contribution in kind of shares held by them in Eurofins Biologie Médicale Ile de France (which they have received in exchange of their minority stake in Eurofins LDP).

As a result, Eurofins Scientific SE issued 3,857 new shares under ISIN code FR0013383189, representing 0.02% of the company’s share capital.

For more information, please visit or contact:

Investor Relations

Eurofins Scientific

Phone: +32 2 766 1620


Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is a scientific leader in food, environment, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the leading global emerging players in specialty clinical diagnostic testing. With about 45,000 staff in more than 800 laboratories across 47 countries, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.